These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23557177)

  • 1. Subcutaneous administration of nano- and microsuspensions of poorly soluble compounds to rats.
    Sigfridsson K; Lundqvist A; Strimfors M
    Drug Dev Ind Pharm; 2014 Apr; 40(4):511-8. PubMed ID: 23557177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor--the importance of gastrointestinal pH and solubility for the in vivo exposure.
    Sigfridsson K; Lundqvist A; Strimfors M
    Drug Dev Ind Pharm; 2011 Sep; 37(9):1036-42. PubMed ID: 21417620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nano- and microcrystals of griseofulvin subcutaneously administered to rats resulted in improved bioavailability and sustained release.
    Sigfridsson K; Rydberg H; Strimfors M
    Drug Dev Ind Pharm; 2019 Sep; 45(9):1477-1486. PubMed ID: 31260340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development.
    Sigfridsson K; Lundqvist AJ; Strimfors M
    Drug Dev Ind Pharm; 2011 Mar; 37(3):243-51. PubMed ID: 21073318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development.
    Sigfridsson K; Lundqvist AJ; Strimfors M
    Drug Dev Ind Pharm; 2009 Dec; 35(12):1479-86. PubMed ID: 19929207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A candidate drug administered subcutaneously to rodents as drug particles showing hepatic recirculation which influenced the sustained release process.
    Sigfridsson K; Arvidsson T; Xue A; Wagner DJ; Pop-Damkov P; Zhang G; Strimfors M
    Int J Pharm; 2020 May; 581():119252. PubMed ID: 32240808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of exposure properties after injection of nanosuspensions and microsuspenions into the intraperitoneal space in rats.
    Sigfridsson K; Lundqvist A; Strimfors M
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1832-9. PubMed ID: 23240709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base.
    Hecq J; Deleers M; Fanara D; Vranckx H; Boulanger P; Le Lamer S; Amighi K
    Eur J Pharm Biopharm; 2006 Nov; 64(3):360-8. PubMed ID: 16846725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linking
    Nguyen V; Bevernage J; Darville N; Tistaert C; Van Bocxlaer J; Rossenu S; Vermeulen A
    Mol Pharm; 2021 Mar; 18(3):952-965. PubMed ID: 33400546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound.
    Sigfridsson K; Forssén S; Holländer P; Skantze U; de Verdier J
    Eur J Pharm Biopharm; 2007 Sep; 67(2):540-7. PubMed ID: 17383167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters.
    Bittner B; Mountfield RJ
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):59-71. PubMed ID: 11865674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic evaluation of poorly soluble compounds formulated as nano- or microcrystals after intraperitoneal injection to mice.
    Aluri KC; Sigfridsson K; Xue A; Hariparsad N; McGinnity D; Ramsden D
    Int J Pharm; 2023 Apr; 636():122787. PubMed ID: 36894042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug nanocrystals - Versatile option for formulation of poorly soluble materials.
    Peltonen L; Hirvonen J
    Int J Pharm; 2018 Feb; 537(1-2):73-83. PubMed ID: 29262301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained release and improved bioavailability in mice after subcutaneous administration of griseofulvin as nano- and microcrystals.
    Sigfridsson K; Xue A; Goodwin K; Fretland AJ; Arvidsson T
    Int J Pharm; 2019 Jul; 566():565-572. PubMed ID: 31181305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical efficacy and safety assessment of nano-oxaliplatin oral formulation prepared by novel Fat Employing Supercritical Nano System, the FESNS®.
    Kim YH; Lee SJ; Lee SH; Hahn M
    Pharm Dev Technol; 2012; 17(6):677-86. PubMed ID: 23216046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of systemic exposure of nanoparticle suspensions subcutaneously administered to mice regarding stabilization, volume, location, concentration and size.
    Sigfridsson K; Palmer M
    Drug Dev Ind Pharm; 2014 Oct; 40(10):1318-24. PubMed ID: 23879245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications.
    Deng Z; Xu S; Li S
    Int J Pharm; 2008 Mar; 351(1-2):236-43. PubMed ID: 18093763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uniform nano-sized valsartan for dissolution and bioavailability enhancement: influence of particle size and crystalline state.
    Ma Q; Sun H; Che E; Zheng X; Jiang T; Sun C; Wang S
    Int J Pharm; 2013 Jan; 441(1-2):75-81. PubMed ID: 23266761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Method for screening of solid dispersion formulations of low-solubility compounds--miniaturization and automation of solvent casting and dissolution testing.
    Shanbhag A; Rabel S; Nauka E; Casadevall G; Shivanand P; Eichenbaum G; Mansky P
    Int J Pharm; 2008 Mar; 351(1-2):209-18. PubMed ID: 18054181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.